T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients

Journal of Clinical Investigation

Volumn 125, Issue 8, 2015, Pages 3063-3076

  Boag, Stephen E ^a   Das, Rajiv ^b   Shmeleva, Evgeniya V ^a   Bagnall, Alan ^a,b   Egred, Mohaned ^a,b   Howard, Nicholas ^c   Bennaceur, Karim ^a   Zaman, Azfar ^a,b   Keavney, Bernard ^a,d   Spyridopoulos, Ioakim ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SUNDERLAND   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CX3CL1 PROTEIN, HUMAN; FRACTALKINE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; HEART MUSCLE BLOOD FLOW; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROVASCULAR OBSTRUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REPERFUSION INJURY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VASCULAR DISEASE; BLOOD; CD4 LYMPHOCYTE COUNT; COMPLICATION; HEART INFARCTION; LYMPHOPENIA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CX3CL1; FEMALE; HUMANS; LYMPHOPENIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84939217893     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80055     Document Type: Article

References (37)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-1135.
2. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol. 2009;104(2):189-202.
3. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61(3):481-497.
4. Ito H. No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications. Acta Med Okayama. 2009;63(4):161-168.
5. Huang Y, Rabb H, Womer KL. Ischemia-reperfusion and immediate T cell responses. Cell Immunol. 2007;248(1):4-11.
6. Yang Z, et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 2005;111(17):2190-2197.
7. + T lymphocytes. Circulation. 2006;114(19):2056-2064.
8. Dragu R, et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis. 2008;196(1):405-412.
9. Cho KH, et al. Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2011;107(6):849-856.
10. Han YC, et al. Neutrophil to lymphocyte ratio predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Korean Circ J. 2013;43(2):93-99.
11. Horne BD, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45(10):1638-1643.
12. Kaya MG, et al. Prognostic value of neutrophil/ lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol. 2013;168(2):1154-1159.
13. Shen XH, Chen Q, Shi Y, Li HW. Association of neutrophil/lymphocyte ratio with long-term mortality after ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Chin Med J (Engl). 2010;123(23):3438-3443.
14. Bodí V, et al. Post-reperfusion lymphopenia and microvascular obstruction in ST-segment elevation acute myocardial infarction. Rev Esp Cardiol. 2009;62(10):1109-1117.
15. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
16. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519-1530.
17. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemost. 2007;97(5):738-747.
18. Dimitrov S, Benedict C, Heutling D, Westermann J, Born J, Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood. 2009;113(21):5134-5143.
19. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol. 2004;24(1):34-40.
20. Akpek M, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012;110(5):621-627.
21. Kurtul A, et al. Usefulness of the platelet-tolymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(3):342-347.
22. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92-100.
23. Piot C, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359(5):473-481.
24. Azzi JR, Sayegh MH, Mallat SG. Calcineurin inhibitors: 40 years later, can't live without. J Immunol. 2013;191(12):5785-5791.
25. Damås JK, et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol. 2005;25(12):2567-2572.
26. + -T-cell cytokine response induces fractalkine in endothelial cells. J Virol. 2004;78(23):13173-13181.
27. Bolovan-Fritts CA, Spector SA. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood. 2008;111(1):175-182.
28. Njerve IU, Solheim S, Lunde K, Hoffmann P, Arnesen H, Seljeflot I. Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection. Cytokine. 2014;69(1):131-135.
29. 3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin. J Exp Med. 2014;211(6):1185-1196.
30. Nanki T, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum. 2002;46(11):2878-2883.
31. Broux B, et al. CX(3)CR1 drives cytotoxic CD4(+) CD28(-) T cells into the brain of multiple sclerosis patients. J Autoimmun. 2012;38(1):10-19.
32. Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol. 2012;52(4):873-882.
33. Hofmann U, Frantz S. Role of lymphocytes in myocardial injury, healing, and remodeling after myocardial infarction. Circ Res. 2015;116(2):354-367.
34. Hoffmann J, et al. High-throughput 13-parameter immunophenotyping identifies shifts in the circulating T-cell compartment following reperfusion in patients with acute myocardial infarction. PLoS One. 2012;7(10):e47155.
35. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008;5:6.
36. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708-712.
37. Vermes E, Childs H, Carbone I, Barckow P, Friedrich MG. Auto-threshold quantification of late gadolinium enhancement in patients with acute heart disease. J Magn Reson Imaging. 2013;37(2):382-390.